Division of Critical Care, Department of Medicine, Hamad Medical Corporation, Doha, Qatar.
Division of Critical Care, Department of Pharmacy, Hamad Medical Corporation, Doha, Qatar.
J Hosp Infect. 2021 Apr;110:165-171. doi: 10.1016/j.jhin.2021.01.027. Epub 2021 Feb 6.
We investigated the clinical characteristics and risk factors for the isolation of multi-drug-resistant (MDR) Gram-negative bacteria (GNB) from critically ill COVID-19 patients.
We retrospectively matched (1:2) critical COVID-19 patients with one or more MDR GNB from any clinical specimen (cases), with those with no MDR GNB isolates (controls).
Seventy-eight cases were identified (4.5 per 1000 intensive care unit (ICU) days, 95% confidence interval (CI) 3.6-5.7). Of 98 MDR GNB isolates, the most frequent species were Stenotrophomonas maltophilia (24, 24.5%), and Klebsiella pneumoniae (23, 23.5%). Two (8.7%) K. pneumoniae, and six (85.7%) Pseudomonas aeruginosa isolates were carbapenem resistant. A total of 24 (24.5%) isolates were not considered to be associated with active infection. Those with active infection received appropriate antimicrobial agents within a median of one day. The case group had significantly longer median central venous line days, mechanical ventilation days, and hospital length of stay (P<0.001 for each). All-cause mortality at 28 days was not significantly different between the two groups (P=0.19). Mechanical ventilation days (adjusted odds ratio 1.062, 95% CI 1.012-1.114; P=0.015), but not receipt of corticosteroids or tocilizumab, was independently associated with the isolation of MDR GNB. There was no association between MDR GNB and 28-day all-cause mortality (adjusted odds ratio 2.426, 95% CI 0.833-7.069; P= 0.104).
In critically ill COVID-19 patients, prevention of MDR GNB colonization and infections requires minimizing the use of invasive devices, and to remove them as soon as their presence is no longer necessary.
我们研究了从危重症 COVID-19 患者中分离出多重耐药(MDR)革兰氏阴性菌(GNB)的临床特征和危险因素。
我们回顾性地将任何临床标本中分离出一种或多种 MDR GNB 的危重症 COVID-19 患者(病例)与未分离出 MDR GNB 株的患者(对照组)进行 1:2 匹配。
共确定了 78 例病例(每 1000 个 ICU 天 4.5 例,95%置信区间 3.6-5.7)。在 98 株 MDR GNB 分离株中,最常见的菌种为嗜麦芽寡养单胞菌(24 株,24.5%)和肺炎克雷伯菌(23 株,23.5%)。2 株(8.7%)肺炎克雷伯菌和 6 株(85.7%)铜绿假单胞菌分离株对碳青霉烯类药物耐药。共有 24 株(24.5%)分离株被认为与活动性感染无关。在接受适当的抗菌药物治疗后,有活动性感染的患者在中位数为 1 天内接受了治疗。病例组的中位中心静脉导管天数、机械通气天数和住院时间明显更长(P<0.001)。两组 28 天全因死亡率无显著差异(P=0.19)。机械通气天数(调整优势比 1.062,95%置信区间 1.012-1.114;P=0.015),而非皮质类固醇或托珠单抗的使用与 MDR GNB 的分离有关。MDR GNB 与 28 天全因死亡率无关联(调整优势比 2.426,95%置信区间 0.833-7.069;P=0.104)。
在危重症 COVID-19 患者中,预防 MDR GNB 定植和感染需要尽量减少使用侵入性设备,并在其不再需要时尽快去除。